Complement-Dependent Cytotoxicity (CDC) to Detect Anti-HLA Antibodies: Old but Gold
| Autor: | Patricia Keiko Saito, Waldir Veríssimo da Silva, Roger Haruki Yamakawa, Lucieni Christina Marques da Silva Pereira, Sueli Donizete Borelli |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Microbiology (medical)
animal structures medicine.diagnostic_test biology Globulin Biochemistry (medical) Clinical Biochemistry Public Health Environmental and Occupational Health Panel reactive antibody Hematology Human leukocyte antigen Molecular biology Complement-dependent cytotoxicity End stage renal disease Transplantation Medical Laboratory Technology Immunoassay Immunology medicine biology.protein Immunology and Allergy Antibody health care economics and organizations |
| Zdroj: | Journal of Clinical Laboratory Analysis. 28:275-280 |
| ISSN: | 0887-8013 |
| DOI: | 10.1002/jcla.21678 |
| Popis: | Background The criterion (gold) standard to detect anti-human leukocyte antigen (HLA) antibodies is the complement-dependent cytotoxicity (CDC) assay. Recently, more sensitive methods have been used for the same purpose. Methods This study analyzed 70 serum samples of patients with end-stage renal disease using CDC, CDC with the addition of anti-human globulin (CDC-AHG), CDC with the addition of dithiothreitol (CDC-DTT), and the recent solid-phase immunoassay (SPI; Labscreen PRA) to detect anti-HLA antibodies. Results Mean percent panel reactive antibodies (PRA) detected by SPI was 37.5% (±34.2) higher than the values detected by the other methods. Comparative analyses revealed significant difference between CDC and CDC-AHG, and between CDC and SPI (P < 0.0001), but not between CDC-AHG and SPI (P = 0.8026). Conclusion Although the CDC-AHG method is “old,” its performance to detect anti-HLA antibodies in the samples analyzed was comparable to the SPI in the evaluation of percent class I PRA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|